IOL Chemicals and Pharmaceuticals share news and announcements
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
Last close ₹164.14down ₹7.22 (4.21%)BSE ₹163.40
Share price at the NSE close on 23 Oct 2026. Previous close ₹171.36.
52-week range of traded prices to 23 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,818 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 28.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 31,10,55637.2% delivered
IOL Chemicals and Pharmaceuticals share news and announcements
716 announcements, routine notices left out, newest first. Page 13 of 15.
May 2015
Apr 2015
Mar 2015
Feb 2015
5 Feb · Board meeting
Inter alia to consider and approve the un-audited financial results of the Company for the quarter ended December 31, 2014.
Dec 2014
16 Dec · Updates
Company has once again won the National Energy Conservation Award 2014. The Company has won the Second PRIZE in Chemical Sector for its continued efforts towards new technology implementation so as to conserve energy resources of the country. Mr Damandeep Singh, Vice President, IOLCP received the award from Sh. Pyush Goyal - Power Minister at a special felicitation ceremony held on December 14, 2014, National Energy Conservation Day, at New Delhi.1 Dec · Board meeting
Board of Directors in its meeting held on November 28, 2014 has considered and approved the following matters: 1. Un-audited financial results for the quarter/half year ended 30 September 2014 2. Allotment of 50,51,924 equity shares of face value of Rs 10/- each on conversion of US$ six million Zero Coupon Unsecured Foreign Currency Convertible Bonds issued in May 2010 to the bondholders and allotment of 8,41,987 equity shares of the face value Rs 10/- each on conversion of US $ one million bonds in the name of custodian on behalf of the bondholders, who have not submitted their conversion notices for mandatory conversion. The paid up capital of the company increased from 4,17,61,591 equity shares of Rs 10/- each to 4,76,55,502 equity shares of Rs 10/- each on the allotment aforesaid shares. 3. Constituted a Committee with M/s KPMG as its advisors, to unleash the potential of the company through the various options of joint ventures, restructuring of business etc.
Nov 2014
14 Nov · Business
Allotment Committee of the Board of Directors in its meeting held on November 14, 2014 allotted 10,00,000 equity shares of Rs. 10/- each to M/s Innova Marchantiles Limited, Non-Promoter on the exercise of option attached with the warrants allotted on July 4, 2014. Consequent upon the issue of the above 10,00,000 equity shares, the total paid-up capital of the company stands increased to 4,10,11,591 fully paid equity shares of Rs.10/- each.13 Nov · Business
Allotment Committee of the Board of Directors in its meeting held on November 13, 2014 allotted 7,00,000 equity shares of Rs. 10/- each to M/s Innova Marchantiles Limited, Non-Promoter on the exercise of option attached with the warrants allotted on July 04, 2014. Consequent upon the issue of the above 7,00,000 equity shares, the total paid-up capital of the Company stands increased to 4,00,11,591 fully paid equity shares of Rs. 10/- each.
Oct 2014
29 Oct · Board meeting
27 Oct · Board meeting
Inter-alia to consider to exercise CALL OPTION by the company to convert FCCBs into equity shares.7 Oct · Updates
As per the Company's Code of Conduct for Prohibition of Insider Trading framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the Trading Window for dealing in the securities of the Company will be closed for the purpose of declaration of financial results of the Company for the quarter ended September 30, 2014 for all the Designated Employees (including Directors) of the Company from October 01, 2014 upto 48 hours of the conclusion of the Board Meeting in which the financial results for the quarter/half year ended September 30, 2014 are to be considered and approved. Accordingly all the Designated Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of Trading Window.
Sep 2014
30 Sep · Disclosure of Voting Pattern - Clause 35A
Aug 2014
25 Aug · Updates
Company pursuant to para 6.3.12 of the Terms and Conditions relating to adjustment of conversion price in connection with the Zero Coupon Unsecured Foreign Currency Convertible Bonds ( FCCB) issued by the company in May 2010 , the Committee of the Board in its meeting held on July 4, 2014 has allotted 11,50,000 equity shares of face value of Rs.10/- at a price of Rs.28/- per share and 1,10,00,000 warrants with option to subscribe a share for each warrant at a price of Rs.28/- per shares within a period of 18 month from the date of allotment pursuant to the meeting of Board of Directors held on May 21, 2014 and shareholders meeting held on June 20, 2014 and accordingly the conversion price of said Bonds stands adjusted from date of allotment that is from July 4, 2014 from Rs. 78 to Rs. 77 per share.25 Aug · Meeting
Annual General Meeting of the members of the Company will be held on September 30, 2014. Further, the Register of Members and the Share Transfer Books will remain closed from September 23, 2014 to September 30, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company.22 Aug · Board meeting
Board at its meeting held on August 22, 2014 approved the following: 1. The Board has approved the appointment of Dr Sandhya Mehta, as Additional and Independent Director w.e.f 22 August 2014. She has vast 22 experience to her credit. She has published seven books in addition to numerous papers published in reputed National & International Journals. She holds master degree in Business Management and Ph.D.14 Aug · Board meeting
1 Aug · Board meeting
Inter-alia to consider and approve the un-audited financial results of the Company for the quarter ended 30 June 2014.
Jul 2014
21 Jul · Updates
Company has obtained "Certificate of Good Manufacturing Practices Compliance of Manufacturer" from Authority for Health and Consumer Protection, Hamburg, Germany. This is in addition to the "Certificate of Suitability" already obtained from European Directorate for the Quality of Medicines and Healthcare, (EDQM) France. This will facilitate the company to improve the sale of Ibuprofen in the European Countries.7 Jul · Board meeting
File name: “Outcome_of_Allotment_committee_04”
Jun 2014
23 Jun · Disclosure of Voting Pattern - Clause 35A
May 2014
30 May · Board meeting
Board of Directors in its meeting held on May 30, 2014 has considered and approved the following matters:(1) Constituted ESOP Compensation Committee to formulate, administer and supervise the Employee Stock Option Scheme.20 May · Board meeting
Inter alia to consider the preferential issue of shares/ warrants to the promoters and non-promoters of the Company.15 May · Board meeting
Inter-alia to consider and approve the audited financial results of the Company for the quarter and the financial year ended March 31, 2014.
Apr 2014
4 Apr · Updates
The Trading Window was closed w.e.f. April 01, 2014 upto 48 hours of the conclusion of the Board Meeting in which the financial results for the quarter/year ended March 31, 2014 are to be considered and approved.
Mar 2014
19 Mar · Disclosure of Voting Pattern - Clause 35A
Feb 2014